Arcutis Signals Potential Tender Offer with 8-K Filing

TL;DR

**Arcutis just hinted at a tender offer, watch for potential stock price movement.**

AI Summary

Arcutis Biotherapeutics, Inc. filed an 8-K on January 11, 2024, indicating it is engaging in "Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." This specific filing suggests the company is preparing for a tender offer, which is a public offer to all shareholders to buy their shares at a specific price, often above market value. For investors, this matters because a tender offer could significantly impact the stock's price and ownership structure, potentially leading to a premium for current shareholders or a change in company control.

Why It Matters

This filing signals Arcutis Biotherapeutics, Inc. is likely preparing for a tender offer, which could provide an opportunity for shareholders to sell their stock at a premium or indicate a significant change in company ownership or strategy.

Risk Assessment

Risk Level: medium — While a tender offer can be beneficial, the specifics (price, conditions) are unknown, introducing uncertainty and potential for market volatility.

Analyst Insight

A smart investor would closely monitor Arcutis Biotherapeutics, Inc. (ARQT) news for details on the potential tender offer, as it could present an opportunity to sell shares at a premium or signal a strategic shift. Reviewing the company's fundamentals and the potential offer price will be crucial.

Key Players & Entities

• Arcutis Biotherapeutics, Inc. (company) — the registrant filing the 8-K
• January 11, 2024 (date) — date of earliest event reported and filing date
• Rule 13e-4(c) (other) — SEC rule governing pre-commencement communications for tender offers
• 001-39186 (other) — Commission File Number for Arcutis Biotherapeutics, Inc.
• ARQT (other) — trading symbol for Arcutis Biotherapeutics, Inc. Common Stock

Forward-Looking Statements

• Arcutis Biotherapeutics, Inc. will announce the specific terms of a tender offer. (Arcutis Biotherapeutics, Inc.) — medium confidence, target: 2024-03-31
• ARQT stock price will experience increased volatility. (ARQT) — high confidence, target: 2024-02-29

FAQ

Key Financial Figures

• $0.0001 — ich registered Common Stock, par value $0.0001 per share ARQT The Nasdaq Global Select
• $10.00 — exercise price equal to or greater than $10.00 (the "Minimum Exercise Price"). Option
• $19.99 — ment RSU Award to be Granted $10.00 - $19.99 2 to 1 $20.00 - $27.49 2.5 to 1 >=
• $20.00 — o be Granted $10.00 - $19.99 2 to 1 $20.00 - $27.49 2.5 to 1 >= $27.50 3 to 1
• $27.49 — ted $10.00 - $19.99 2 to 1 $20.00 - $27.49 2.5 to 1 >= $27.50 3 to 1 The newly
• $27.50 — 2 to 1 $20.00 - $27.49 2.5 to 1 >= $27.50 3 to 1 The newly issued RSUs are expe

Filing Documents

• arqt-20240111.htm (8-K) — 42KB
• exhibit991-toxc.htm (EX-99.1) — 11KB
• exhibit991-toxc001.jpg (GRAPHIC) — 79KB
• exhibit991-toxc002.jpg (GRAPHIC) — 77KB
• exhibit991-toxc003.jpg (GRAPHIC) — 117KB
• exhibit991-toxc004.jpg (GRAPHIC) — 134KB
• exhibit991-toxc005.jpg (GRAPHIC) — 124KB
• exhibit991-toxc006.jpg (GRAPHIC) — 74KB
• exhibit991-toxc007.jpg (GRAPHIC) — 117KB
• exhibit991-toxc008.jpg (GRAPHIC) — 173KB
• exhibit991-toxc009.jpg (GRAPHIC) — 107KB
• exhibit991-toxc010.jpg (GRAPHIC) — 133KB
• 0001628280-24-001150.txt ( ) — 1752KB
• arqt-20240111.xsd (EX-101.SCH) — 2KB
• arqt-20240111_lab.xml (EX-101.LAB) — 24KB
• arqt-20240111_pre.xml (EX-101.PRE) — 13KB
• arqt-20240111_htm.xml (XML) — 3KB

01 Other Events

Item 8.01 Other Events. On January 11, 2024, Arcutis Biotherapeutics, Inc. (the "Company") announced that certain eligible employees and consultants will be invited to participate in a voluntary, one-time opportunity to exchange certain outstanding eligible options to purchase shares of the Company's common stock, par value $0.0001 per share (the "Common Stock"), for a lesser number of new restricted stock units ("RSUs") pursuant to an option exchange program (the "Option Exchange"). The Company is pursuing this initiative as part of its continued efforts to retain top tier talent, and in recognition that its employees and consultants value their equity holdings in the Company. An objective of the Company's equity incentive programs has been, and continues to be, to align the interests of employees and consultants with those of the Company's stockholders, and the Company believes that the Option Exchange is an important component its efforts to achieve that goal. The Company views equity as a meaningful component of its compensation philosophy and strives to remain competitive in its compensation offerings to employees. Only eligible options may be exchanged in the Option Exchange. For these purposes "eligible options" are expected to be those options that: are held by an employee or consultant of the Company or its subsidiaries as of the date of grant for the replacement RSU award, which is expected to be the offer expiration date; and have a per share exercise price equal to or greater than $10.00 (the "Minimum Exercise Price"). Options held by an individual who is not an employee or consultant of the Company or its subsidiaries as of the date of grant for the replacement RSU award or having an exercise price less than the Minimum Exercise Price will not be eligible to be exchanged in the Option Exchange. Further, participants in the Option Exchange may exchange all or none of each eligible option grant. Partial exchanges of a grant are not permitted. Indivi

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Communication to Eligible Participants 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. ARCUTIS BIOTHERAPEUTICS, INC. Date: January 11, 2024 By: /s/ Todd Franklin Watanabe Todd Franklin Watanabe President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR